替比夫定治疗慢性乙型肝炎疗效的系统评价

表3 LDT组与LAM组对比其HBV DNA检测不到率结果

HBeAg	疗程(wk)	纳入研究数	LDT组/LAM组(n)	P值, I2值	DNA转阴率(LDT组/LAM组)	RR值(95%CI)
阳性	48	1个[12]	56/52	-	60.71%/40.38%	1.50(1.02, 2.22)
	52	4个[6-8,11]	709/685	0.45, 0%	62.34%/40.58%	1.54(1.38, 1.72)
	104	1个[5]	458/463	-	55.60%/55.60%	1.45(1.26, 1.67)
	总疗程	6个	1 223/1 200	0.70, 0%	59.77%/39.75%	1.50(1.38, 1.64)
	敏感性分析	3个[5,6,8]	1 063/1 069	0.36, 1%	59.08%/39.20%	1.51(1.38, 1.65)
阴性	48	1个[12]	29/27	-	差异无统计学意义	0.99(0.66, 1.48)
	52	3个[6,8,11]	302/306	0.59, 0%	86.09%/69.28%	1.24(1.14, 1.36)
	104	1个[5]	222/224	-	82.00%/56.70%	1.45(1.27, 1.65)
	总疗程	5个	553/557	0.15, 41%	83.18%/63.91%	1.30(1.21, 1.40)
	敏感性分析	3个[5,6,8]	464/470	0.08, 61%	85.13%/64.68%1	1.29(1.12, 1.48)1

¹随机效应模型.